Back to top
more

ESSA Pharma (EPIX)

(Delayed Data from NSDQ)

$6.39 USD

6.39
94,069

+0.09 (1.43%)

Updated May 24, 2024 04:00 PM ET

After-Market: $6.26 -0.13 (-2.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

ESSA Pharma Inc. [EPIX]

Reports for Purchase

Showing records 41 - 52 ( 52 total )

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 41

03/26/2018

Company Report

Pages: 19

The Phoenix Should Rise Now That the Heavy Lifting Is Done; Initiating at Buy, $0.70 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 42

02/20/2018

Company Report

Pages: 6

Plans to build on the strengths of its EPI-506 chemical scaffold

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 25.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 43

01/18/2018

Company Report

Pages: 4

Cashed-up + Great Target + Lessons Learned

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 44

12/18/2017

Daily Note

Pages: 22

2018 Top Ideas; Healthcare Sector Review/Preview

Provider: Bloom Burton & Company

Price: 75.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 45

09/12/2017

Daily Note

Pages: 3

EPI-506 Phase 1 Provides Some POC But PK Hurdles Too High

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 46

08/02/2017

Company Report

Pages: 16

We are initiating coverage with a BUY rating and 12-18 month price target of $2.20 per share

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: WASSERMAN R

Price: 50.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 47

06/06/2017

Company Report

Pages: 4

6th Cohort Data Adds Uncertainty

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 48

05/18/2017

Company Report

Pages: 3

First Hints of EPI-506 Efficacy - More Data at ASCO.

Provider: Bloom Burton & Company

Analyst: MARTIN D

Price: 10.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 49

01/04/2017

Daily Note

Pages: 17

2017 Top Ideas; Healthcare Sector Review/Preview

Provider: Bloom Burton & Company

Price: 50.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 50

04/11/2016

Company Report

Pages: 5

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 51

09/24/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ESSA Pharma Inc.

Industry: Medical - Drugs

Record: 52

09/24/2015

Daily Note

Pages: 4

Back on Track, IND is Allowed

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party